Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer clot care under the microscope: new study mines data for better treatment insights

NCT ID NCT04618913

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study reviews existing medical records to understand how blood clots (VTE) are treated in people with active cancer or a history of cancer. Researchers will look at which blood thinners are used, how often clots come back, and the costs involved. No new treatments are given—this is purely an analysis of past data to guide future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1 person

The number who actually took part.

Started

Dec 2020

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with a diagnosis of (VTE) venous thromboembolism and active cancer, or a history of cancer, being treated with anticoagulation.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A VTE diagnosis * Active cancer or history of cancer * Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH * Age ≥ 18 years at the date of index VTE (Venous thromboembolic) Exclusion Criteria: * Prior VTE diagnosis * Diagnosis of prior atrial fibrillation * Inferior Vena Cava (IVC) filter * Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed. * Pregnancy * More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date. * Patients with less than one day of follow up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Embolism neoplasm venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Embolism Neoplasms

Contacts and locations

Locations

  • Pfizer Investigational Site

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.